Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - furosemide, quantity: 20 mg - injection, solution - excipient ingredients: sodium hydroxide; water for injections; sodium chloride; hydrochloric acid - oedema: furosemide-baxter injection is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. furosemide-baxter injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by the intravenous route. parenteral use should be replaced with oral frusemide as soon as practical.

Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - mesna - solution for inj/inf - 100 mg/ml - mesna

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - fluconazole 2 mg/ml - solution for infusion - 0.2% w/v - active: fluconazole 2 mg/ml excipient: hydrochloric acid sodium chloride water for injection - cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary, cutaneous). normal hosts, and patients with aids, organ transplants or other causes of immunosuppression may be treated. fluconazole-claris can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with aids.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - flumazenil 0.1 mg/ml - solution for injection - 0.1 mg/ml - active: flumazenil 0.1 mg/ml excipient: disodium edetate glacial acetic acid sodium chloride sodium hydroxide water for injection - for reversal of the centrally sedative effects of benzodiazepines. it should therefore be used in anaesthesia and intensive care in the following indications: in anaesthesia: -termination of general anaesthesia induced and maintained with benzodiazepines in inpatients. -reversal of benzodiazepine sedation in short diagnostic and therapeutic procedures in both inpatients and outpatients. -reversal of paradoxical reactions due to benzodiazepines. in intensive care and in the management of unconsciousness of unknown origin: -for the diagnosis and/or management of benzodiazepine overdose due to self-poisoning or accidental overdose. -as a diagnostic measure in unconsciousness of unknown origin to differentiate between involvement of benzodiazepines, other medicines or drugs or brain damage. -flumazenil-claris may also be used for specific reversal of the central effects of benzodiazepines in drug or medicine overdose (return to spontaneous respiration and consciousness in order to render intubation unnecessary or allow extubation).

Իսրայել - անգլերեն - Ministry of Health

baxter healthcare distribution ltd., israel - glucose as monohydrate - solution for infusion - glucose as monohydrate 500 g / 1 l - glucose - high caloric carbohydrate infusion, hypoglycaemia

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - bupivacaine hydrochloride, quantity: 5 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 5.28 mg/ml) - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; water for injections; sodium hydroxide - indications ,bupivacaine-claris is indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: ,surgical anaesthesia ,epidural block for surgery ,field block (minor and major nerve blocks and infiltration). ,analgesia ,continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. ,field block (minor nerve block and infiltration).

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - lidocaine hydrochloride monohydrate, quantity: 53.3 mg (equivalent: lidocaine hydrochloride, qty 50 mg) - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium chloride; sodium hydroxide - for production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - lidocaine hydrochloride monohydrate, quantity: 213.2 mg (equivalent: lidocaine hydrochloride, qty 200 mg) - injection, solution - excipient ingredients: water for injections; sodium chloride; hydrochloric acid; sodium hydroxide - for production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - lidocaine hydrochloride monohydrate, quantity: 42.66 mg (equivalent: lidocaine hydrochloride, qty 40 mg) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; sodium chloride; hydrochloric acid - for production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - lidocaine hydrochloride monohydrate, quantity: 21.32 mg (equivalent: lidocaine hydrochloride, qty 20 mg) - injection, solution - excipient ingredients: sodium hydroxide; sodium chloride; hydrochloric acid; water for injections - for production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.